medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (1)

Algorithm for diagnosis and treatment of thymus hypoplasia in childhood, associated or not with immune deficiency

de la Guardia POM

Language: Spanish
References: 12
Page: 1-12
PDF size: 309.57 Kb.


ABSTRACT

About 20 years ago, a group of Cuban medical researchers reported to the literature the use of measurements of the thymus by ultrasonography, as a valid weapon in the immunological evaluation of children under 7 years of age with frequent infections, mainly respiratory. The range of normality proposed for the area of the thymic silhouette is between 1010.6 - 1425.4 mm2, that is, 1 218 ± 207.4 mm2. Below and above these values, we would speak of hypoplasia and hyperplasia, respectively. Severe hypoplasia is considered when the thymic area is less than 500 mm2; moderate when it is between 500 and 799 mm2 and mild when it is between 800 and 999 mm2. A diagnosis and treatment algorithm is proposed that encompasses the clinical experience of 12 years of work in pediatric clinical immunology at the Institute of Hematology and Immunology. It can be a useful tool in the hands of pediatric clinical immunologists who would adapt the ideal treatment to bring the organ to its standard size with the consequent decrease in infectious processes and the elevation of immunoglobulin A levels in patients.


REFERENCES

  1. Seoane Reula ME, de Arriba Méndez S. Diagnóstico y manejo de las inmunodeficiencias primarias en niños. Protoc diagn ter pediatr [Internet]. 2019 [acceso 27/03/2021];2:415-35. Disponible en: https://www.aeped.es/sites/default/files/documentos/28_imunodeficiencias_primarias.pdf

  2. Macías Abraham C. Una mirada al diagnóstico y tratamiento de las inmunodeficiencias primarias en Cuba. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2019 [acceso 27/03/2021];35(4):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/1178

  3. Abolhassani H, Azizi G, Sharifi L, Yazdani R, Mohsenzadegan M, Delavari S, et al. Global systematic review of primary immunodeficiency registries. Expert Rev Clin Immunol. 2020 Jul; 16(7):717-32. DOI: https://10.1080/1744666X.2020.1801422

  4. McCusker C, Upton J, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):61. DOI: https://10.1186/s13223-018-0290-5

  5. Alonso Valle A, Candelaria Gómez B, Valdés Lanza L. Inmunodeficiencias primarias: un reto para la inmunogenética. Rev Cuba Reumatol [Internet]. 2020 Ago [acceso 27/03/2021];22(2):e828. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962020000200009

  6. Murguía Pérez JG, Pérez-Gaxiola G. Inmunode?ciencia combinada grave: informe de caso. Alergia Inmunol Pediatr. [Internet]. 2020 [acceso 27/03/2021];29(1):37-41. Disponible en: https://www.medigraphic.com/pdfs/alergia/al-2020/al201e.pdf

  7. Fallah S, Mesdaghi M, Mansouri M, Babaie D, Karimi A, Fahimzad S, et al. Severe Combined Immunodeficiency: A Case Series and Review from a Tertiary Pediatric Hospital. Iranian J Allergy Asthma Immunol. [Internet]. 2018 [acceso 27/03/2021];17(2):201-7. Disponible en: https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1457

  8. Pérez LC, Corredera R, Prado OA, Addine BDC, Marrón R. Evolución ecosonográfica e inmunológica en un caso de hipoplasia tímica severa. Introducción de variaciones terapéuticas. 16 de Abril [Internet]. 2017 [acceso 27/03/2021];56(266):170-4. Disponible en: https://www.medigraphic.com/pdfs/abril/abr-2017/abr17266g.pdf

  9. Sánchez Segura M, Marsán Suárez V, Macías Abraham C, Pino Blanco D, Socarrás Ferrer BB, del Valle Pérez LO, et al. Agammaglobulinemia ligada al x o de bruton. Rev Cubana Hematol Inmunol Hemoter [Internet].2014 Dic [acceso 25/03/2021];30(4):395-404. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892014000400011&lng=es.

  10. Rozmus J, Junker A, Thibodeau ML, Grenier D, Turvey SE, Yacoub W, et al. Severe Combined Immunodeficiency (SCID) in Canadian Children: A National Surveillance Study. J Clin Immunol. 2013;33(8):1310-16. DOI: https://10.1007/s10875-013-9952-8

  11. Speckmann C, Uhlmann A, Doerken S , Wolkewitz M, Pohl A, Ehl S. A prospective outcome study of patients with profound combined immunodeficiency (P-CID). LymphoSign Journal [Internet]. 2015 [acceso 25/03/2021];2(2). Disponible en: https://lymphosign.com/doi/full/10.14785/lpsn-2015-0002

  12. Aluri J, Desai M, Gupta M, Dalvi A, Terance A, Rosenzweig SD, et al. Clinical, Immunological, and Molecular Findings in 57 Patients with Severe Combined Immunodeficiency (SCID) From India. Front Immunol. 2019 Feb 4;10:23. DOI: https://10.3389/fimmu.2019.00023




2020     |     www.medigraphic.com